| abstract |
The present invention relates to the mammalian fsh05 gene, a novel gene associated with bipolar affective disorder (BAD) in humans. The invention encompasses fsh05 nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, fsh05 gene products and antibodies directed against such gene products, cloning vectors containing mammalian fsh05 gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of fsh05 and to using such compounds as therapeutic agents in the treatment of fsh05 disorders and neuropsychiatric disorders. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of fsh05 disorders and neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder, and to methods and compositions for the treatment of these disorders. |